Dr. Verma on Palbociclib Plus Fulvestrant for HR+/HER2- Breast Cancer
Sunil Verma, MD, MSEd, FRCPC, discusses the PALOMA-3 trial, which examined palbociclib with or without fulvestrant for the treatment of patients with HR-positive, HER2-negative breast cancer.
Sunil Verma, MD, MSEd, FRCPC, medical director, Louise Temerty Breast Cancer Centre at Sunnybrook Health Sciences Centre, discusses the PALOMA-3 trial, which examined palbociclib with or without fulvestrant for the treatment of patients with HR-positive, HER2-negative breast cancer.
Recent Videos
Related Content
